TIAA Trust National Association Cuts Stock Position in Solventum Co. (NYSE:SOLV)

TIAA Trust National Association decreased its holdings in shares of Solventum Co. (NYSE:SOLV) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,280 shares of the company’s stock after selling 351 shares during the quarter. TIAA Trust National Association’s holdings in Solventum were worth $349,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Solventum during the 3rd quarter valued at about $125,488,000. Boston Partners bought a new stake in Solventum during the fourth quarter worth approximately $110,378,000. Point72 Asset Management L.P. purchased a new stake in Solventum during the third quarter valued at approximately $50,948,000. Nordea Investment Management AB lifted its stake in shares of Solventum by 189.5% in the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock valued at $43,902,000 after purchasing an additional 431,986 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Solventum in the 4th quarter worth approximately $18,583,000.

Solventum Trading Down 1.0 %

SOLV stock opened at $74.78 on Friday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The firm’s 50-day moving average is $75.51 and its 200 day moving average is $71.83. The company has a market capitalization of $12.94 billion and a PE ratio of 27.19. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analyst Upgrades and Downgrades

SOLV has been the topic of several recent research reports. Piper Sandler increased their price target on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. The Goldman Sachs Group increased their target price on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Morgan Stanley raised their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th. Mizuho upped their price target on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. Finally, Bank of America raised their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.